Rosenblatt Maintains Sell on CME Gr, Raises Price Target to $169
Portfolio Pulse from richadhand@benzinga.com
Rosenblatt analyst Andrew Bond maintains a 'Sell' rating on CME Group (NASDAQ:CME) but raises the price target from $161 to $169.
July 06, 2023 | 11:01 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Despite the raised price target from $161 to $169, Rosenblatt maintains a 'Sell' rating on CME Group.
The 'Sell' rating maintained by Rosenblatt indicates a negative outlook for CME Group's stock. However, the raised price target suggests some potential upside, which might create mixed sentiment among investors. This could lead to short-term volatility in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100